Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to Hematology


2 Foods to Avoid While on Eliquis

Cardiology May 31st 2023

Oncology Learning Network

Ciltacabtagene Autoleucel CAR−T-Cell Therapy for Patients with Multiple Myeloma: Results from the Phase 2 CARTITUDE-2 Trial

Hematology May 30th 2023

ClinLab Navigator

Platelet Function Screen

Hematology May 30th 2023

Therapeutic Advances in Hematology

Innovations in Hematopoietic Stem-cell Mobilization: A Review of the Novel CXCR4 Inhibitor Motixafortide

Hematology May 30th 2023

OBR Oncology

Cancer Drug Shortages: Liability Concerns and Fears for Patient Care

Oncologists and cancer drug shortages are creating a crisis, with patient care at risk and legal liabilities looming. In the face of critical cancer drug shortages, oncologists grapple with suboptimal patient care and possible legal liabilities. The issue worsens due to insufficient guidelines for alternative treatment options. A contributing factor is the weak financial incentive for drug manufacturers to produce unprofitable generic drugs, compared to branded ones. Consequently, there’s greater dependence on foreign factories, leading to supply chain hitches and quality control issues. Barbara McAneny, MD, CEO of New Mexico Cancer Center, foresees drug shortages persisting, particularly affecting low-cost treatments. The American Society of Health-System Pharmacists (ASHP) reports shortages of vital oncology drugs like methotrexate, cisplatin, carboplatin, and fluorouracil, crucial for treating various common cancers. Furthermore, the lack of guidelines on alternative treatments exacerbates oncologists’ concerns about patient outcomes and legal liabilities. This absence of direction leaves physicians making crucial decisions single-handedly. In response, the American Society of Clinical Oncology (ASCO) has formed an advisory group to develop clinical guidance during these drug shortages. Immediate recommendations include reprioritizing nonessential use of scarce antineoplastic drugs, increasing interval cycles, reducing doses when clinically acceptable, and selecting evidence-based alternatives. Dr. Jeff Patton, CEO […]

Hematology May 30th 2023

The New England Journal of Medicine

Familial Clonal Hematopoiesis in a Long Telomere Syndrome

Hematology May 30th 2023

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form